HealthyNCT07551986
Building Cognitive Resilience to Vaccine Misinformation Using AI in Europe
A study testing AI-driven chatbot and Social media infographic in people with Healthy, run by London School of Hygiene and Tropical Medicine at 1 site in United Kingdom.
Trial summary
This multi-country trial evaluates an AI chatbot designed to counter cognitive biases and inoculate parents against vaccine misinformation, embedded within a large survey across five European countries (n=5,000). Read more about this study
- Who is it for?
- Ages 20 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- AI-driven chatbot and Social media infographic
- Type of treatment
- Vaccines, Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5,000 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 5 Jun 2026to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Parents or caregivers with children under 18 years old in the five target countries (UK, Netherlands, Croatia, Latvia, and Slovakia); and
- Those who have regular access to a digital device and the internet
Who cannot join
- Participants who do not meet the inclusion criteria.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Kana Kobayashi, MSPH contact
United Kingdom1 site, 1 recruiting
- Recruiting
London School of Hygiene and Tropical Medicine
London
Leesa Lin, +44 20 7927 2555, Leesa.Lin@lshtm.ac.uk
About this study
Official title: Building Cognitive Resilience to Vaccine Misinformation Using Conversational AI: Evidence From a Multi-Country European Randomised Trial
This multi-country trial evaluates an AI chatbot designed to counter cognitive biases and inoculate parents against vaccine misinformation, embedded within a large survey across five European countries (n=5,000). Scaled from a 2026 single-country study, outcomes compare behavioural and attitudinal responses against standard-of-care materials (e.g., UNICEF infographics) to identify effective, scalable misinformation interventions.
Read the detailed description
The aim of this multi-country trial is to identify and quantify the effectiveness of inoculation strategies against vaccine-related misinformation. Building on a single-country study implemented in early 2026 [NCT07488962], the study evaluates an AI chatbot designed to counter cognitive biases, embedded within a larger survey to enable integrated assessment of engagement, behavioural responses, and system performance at scale.
The study will be conducted across five European countries-the United Kingdom, the Netherlands, Croatia, Latvia, and Slovakia-with a total sample of 5,000 parents or caregivers (n=1,000 per country). Participants will complete a structured survey assessing childhood vaccination behaviours, vaccine confidence, trust in information sources, exposure to misinformation, and relevant psychological and sociodemographic factors.
Participants will be randomly assigned to either the intervention or control arm. The intervention arm will receive the AI-based chatbot, while the control arm will receive standard-of-care materials-such as national or international health institute communications (e.g., UNICEF infographics)-that address the same misinformation messages, enabling a direct and rigorous comparison.
The primary outcome is parents' ability to correctly distinguish true from false childhood vaccine statements. Quantitative analyses will include pooled and country-specific models to identify determinants of vaccine confidence and estimate intervention effects. Findings will clarify drivers of declining vaccine confidence and assess whether a scalable AI-based chatbot can reduce vulnerability to misinformation and support informed vaccination decisions.
- Conditions
- Healthy
- Being tested
- AI-driven chatbot, Social media infographic
- Keywords
- childhood vaccine, AI, chatbot, randomized controlled trial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AI-driven chatbotBehavioural
A tailored AI-driven chatbot designed to counter vaccine misinformation.
Social media infographicBehavioural
A UNICEF social media infographic with three "myth vs. fact" statements on vaccination.
| Study group | Role | What they receive |
|---|---|---|
| AI-driven chatbot | Experimental | An interactive, web-based, AI-driven chatbot intervention designed to counter vaccine misinformation. It can be accessed via a personal computer, tablet, or mobile device through a web- browser link. Receives: Behavioral: AI-driven chatbot |
| Social media infographic | Active comparator | A UNICEF social media infographic with three "myth vs. fact" statements on vaccination that correspond to the same misinformation tactics explained by the MindShield chatbot. Receives: Behavioral: Social media infographic |
What is being measured
The primary outcome is the main question the study is designed to answer.
Parental susceptibility to misinformation about childhood vaccination
The primary outcome of this study will assess parental susceptibility to misinformation about childhood vaccination, defined as parents' ability to accurately distinguish between true and false vaccine-related information. This will be measured using ten statements on childhood vaccines, including four true and six false, rumour-related statements. Two of the rumour-related statements correspond to each of the three misinformation tactics introduced by the chatbot and the UNICEF infographic. This measure reflects parents' ability to identify misinformation containing manipulation tactics they were inoculated against and to distinguish true from false information regarding childhood vaccination. Responses will be recorded as "True", "False", or "Don't know". A composite misinformation susceptibility score will be calculated based on the number of correct responses, with higher scores indicating greater ability to identify vaccine misinformation accurately.
Measured: Through study completion, an average of 20-30 minutes
Secondary outcomes (1)
Vaccine confidence
Vaccine confidence will be assessed using three statements addressing whether childhood vaccines are important, safe, and effective. Responses will range from "Strongly agree" to "Strongly disagree", with a "Don't know" option. A composite score ranging from 0 to 100 will be calculated, with higher scores indicating greater vaccine confidence.
Measured: Through study completion, an average of 20-30 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Apr 2026
- Study start5 Jun 2026
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- London School of Hygiene and Tropical Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Leesa Lin, PhD, Principal investigator, London School of Hygiene and Tropical Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07551986
- Sponsor's protocol ID
- LSHTM32877
- Status last verified
- Apr 2026
- First submitted
- 20 Apr 2026
- Last updated
- 29 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Building Cognitive Resilience to Vaccine Misinformation Using Conversational AI: Evidence From a Multi-Country European Randomised Trial
- ClinicalTrials.gov ID
- NCT07551986
- Acronym / sponsor ID
- LSHTM32877
- Conditions
- Healthy
- Keywords
- childhood vaccine, AI, chatbot, randomized controlled trial
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- London School of Hygiene and Tropical MedicineUniversity, hospital or other
- Study start
- 5 Jun 2026 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 27 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This multi-country trial evaluates an AI chatbot designed to counter cognitive biases and inoculate parents against vaccine misinformation, embedded within a large survey across five European countries (n=5,000). Scaled from a 2026 single-country study, outcomes compare behavioural and attitudinal responses against standard-of-care materials (e.g., UNICEF infographics) to identify effective, scalable misinformation interventions.
Detailed description
The aim of this multi-country trial is to identify and quantify the effectiveness of inoculation strategies against vaccine-related misinformation. Building on a single-country study implemented in early 2026 [NCT07488962], the study evaluates an AI chatbot designed to counter cognitive biases, embedded within a larger survey to enable integrated assessment of engagement, behavioural responses, and system performance at scale.
The study will be conducted across five European countries-the United Kingdom, the Netherlands, Croatia, Latvia, and Slovakia-with a total sample of 5,000 parents or caregivers (n=1,000 per country). Participants will complete a structured survey assessing childhood vaccination behaviours, vaccine confidence, trust in information sources, exposure to misinformation, and relevant psychological and sociodemographic factors.
Participants will be randomly assigned to either the intervention or control arm. The intervention arm will receive the AI-based chatbot, while the control arm will receive standard-of-care materials-such as national or international health institute communications (e.g., UNICEF infographics)-that address the same misinformation messages, enabling a direct and rigorous comparison.
The primary outcome is parents' ability to correctly distinguish true from false childhood vaccine statements. Quantitative analyses will include pooled and country-specific models to identify determinants of vaccine confidence and estimate intervention effects. Findings will clarify drivers of declining vaccine confidence and assess whether a scalable AI-based chatbot can reduce vulnerability to misinformation and support informed vaccination decisions.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| AI-driven chatbot | Experimental | Behavioral: AI-driven chatbotAn interactive, web-based, AI-driven chatbot intervention designed to counter vaccine misinformation. It can be accessed via a personal computer, tablet, or mobile device through a web- browser link. |
| Social media infographic | Active comparator | Behavioral: Social media infographicA UNICEF social media infographic with three "myth vs. fact" statements on vaccination that correspond to the same misinformation tactics explained by the MindShield chatbot. |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Parents or caregivers with children under 18 years old in the five target countries (UK, Netherlands, Croatia, Latvia, and Slovakia); and
- Those who have regular access to a digital device and the internet
Key exclusion criteria (1 listed)
- Participants who do not meet the inclusion criteria.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AI-driven chatbotA tailored AI-driven chatbot designed to counter vaccine misinformation. | Behavioural | AI-driven chatbot |
| Social media infographicA UNICEF social media infographic with three "myth vs. fact" statements on vaccination. | Behavioural | Social media infographic |
Primary outcome
Parental susceptibility to misinformation about childhood vaccination
Time frame: Through study completion, an average of 20-30 minutes
The primary outcome of this study will assess parental susceptibility to misinformation about childhood vaccination, defined as parents' ability to accurately distinguish between true and false vaccine-related information. This will be measured using ten statements on childhood vaccines, including four true and six false, rumour-related statements. Two of the rumour-related statements correspond to each of the three misinformation tactics introduced by the chatbot and the UNICEF infographic. This measure reflects parents' ability to identify misinformation containing manipulation tactics they were inoculated against and to distinguish true from false information regarding childhood vaccination. Responses will be recorded as "True", "False", or "Don't know". A composite misinformation susceptibility score will be calculated based on the number of correct responses, with higher scores indicating greater ability to identify vaccine misinformation accurately.
1 secondary outcome
Vaccine confidence
Time frame: Through study completion, an average of 20-30 minutes
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2026.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kana Kobayashi, MSPH contact
Leesa Lin, PhD principal investigator
London School of Hygiene and Tropical Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AI-driven chatbot and Social media infographic in people with Healthy, run by London School of Hygiene and Tropical Medicine at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Leesa Lin, PhD (+44 (0)20 7636 8636, Leesa.Lin@lshtm.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Parental susceptibility to misinformation about childhood vaccination (time frame: Through study completion, an average of 20-30 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2026.